ArticleMolecular and cellular endocrinology2026
Revisiting hypocholesterolemia during prolonged sepsis: From targeted cholesterol repletion to unresolved adrenal and muscle dysfunction.
Article in Molecular and cellular endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSepsis HDL- and LDL-hypocholesterolemia associate with adverse outcomes, but whether this necessitates supplementation or merely reflects disease severity remains unclear. We hypothesize that sustained hypocholesterolemia can contribute to ICU-acquired weakness and adrenal dysfunction, and that cholesterol supplementation can improve tissue cholesterol availability, muscle and adrenal integrity.
methodsIn a catheterized mouse model of cecal-ligation-and-puncture-induced sepsis (5-days), septic mice received continuous infusion with an LDL- (mouse study 1; n = 51) (3.5 mg/d) or HDL-cholesterol (mouse study 2; n = 47) (5 mg/d) enriched cholesterol mixture, compared to placebo, and healthy reference mice. Plasma HDL-, LDL-cholesterol, CORT, TNF-α and total bile acids were measured, in addition to muscle force, myofiber cholesterol, ex-vivo adrenal ACTH response, adrenal cholesterol and structure. Gene expression markers of cholesterol synthesis were measured in liver, adrenal and muscle tissue.
resultsLDL-cholesterol infusion in septic mice increased plasma LDL-, but not HDL-cholesterol, whereas HDL-cholesterol infusion increased plasma HDL- and LDL-cholesterol (P < 0.0001 versus placebo). Cholesterol supplementation attenuated sepsis-induced adrenal cholesterol depletion (P < 0.05), without improving adrenocortical structure or the adrenal ACTH response. Cholesterol supplementation did not affect muscle mass loss, force or myofiber cholesterol, but increased plasma bile acids and reduced markers of cholesterol synthesis in liver, adrenal and muscle versus placebo (P ≤ 0.05). No additional effect on elevated plasma CORT and TNF-α was observed.
conclusionCholesterol supplementation reversed sepsis-induced hypocholesterolemia, without reversing the sepsis-induced adrenal or muscle phenotype. Together with suppressed markers of cholesterol uptake, synthesis and increased bile acid formation, these findings argue against the need to treat hypocholesterolemia during prolonged sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.